News & Updates

In adults with obesity but without diabetes, treatment with the oral small-molecule, nonpeptide glucagon-like peptide-1 receptor agonist (GLP-1RA) orforglipron yields substantial reductions in body weight, as shown in the phase III ATTAIN-1 trial.

The use of direct oral anticoagulants (DOACs) appears to be safer than warfarin for patients with nonvalvular atrial fibrillation (AF) and liver cirrhosis (LC), suggests a study. This is particularly true to reducing the risk of major bleeding in those with Child-Pugh class A disease.

Treatment with the combination of pembrolizumab plus chemotherapy elicits response in patients with advanced penile squamous cell carcinoma (PSCC) while having a manageable safety profile, according to the phase II HERCULES trial.

Antenatal administration of betamethasone in women with twin pregnancies at risk of late preterm delivery appears to reduce the risk of neonatal respiratory morbidity, as shown in a study.

For some patients with Crohn’s disease (CD) who show no response to induction treatment with risankizumab, extending the treatment course is safe and improves clinical and endoscopic outcomes, as shown in a study.